University of Hertfordshire

From the same journal

By the same authors

  • Elena Nikiphorou
  • Charlotte Davies
  • Miranda Mugford
  • Nicola Cooper
  • Alan Brooksby
  • Diane K. Bunn
  • Adam Young
  • Suzanne M. Suzanne
  • Deborah P. Deborah
  • Alex J. MacGregor
View graph of relations
Original languageEnglish
Number of pages5
Pages (from-to)794-798
JournalJournal of Rheumatology
Journal publication date1 May 2015
Volume42
Issue5
DOIs
Publication statusPublished - 1 May 2015

Abstract

Objectives. To explore the change in direct medical costs associated with inflammatory polyarthritis (IP) 10 to 15 years after its onset. Methods. Patients from the Norfolk Arthritis Register who had previously participated in a health economic study in 1999 were traced 10 years later and invited to participate in a further prospective questionnaire-based study. The study was designed to identify direct medical costs and changes in health status over a 6-month period using previously validated questionnaires as the primary source of data. Results.A representative sample of 101 patients with IP from the 1999 cohort provided complete data over the 6-month period. The mean disease duration was 14 years (SD 2.1, median 13.6, interquartile range 12.6-15.4). The mean direct medical cost per patient over the 6-month period was £1496 for IP (inflated for 2013 prices). This compared with £582 (95% CI £355-£964) inflated to 2013 prices per patient with IP 10 years earlier in their disease. The increased cost was largely associated with the use of biologics in the rheumatoid arthritis subgroup of patients (51% of total costs incurred). Other direct cost components included primary care costs (11%), hospital outpatient (19%), day care (12%), and inpatient stay (4%). Conclusion. The direct healthcare costs associated with IP have more than doubled with increasing disease duration, largely as a result of the use of biologics. The results showed a shift in the direct health costs from inpatient to outpatient service use.

ID: 13380193